.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Citi
US Department of Justice
Farmers Insurance
Express Scripts
Dow
Mallinckrodt
Fish and Richardson
Johnson and Johnson
Cipla

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,617,598

« Back to Dashboard

Which drugs does patent 8,617,598 protect, and when does it expire?


Patent 8,617,598 protects AFINITOR DISPERZ and is included in one NDA. There has been one Paragraph IV challenge on Afinitor Disperz.

Protection for AFINITOR DISPERZ has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 8,617,598

Title:Pharmaceutical compositions comprising colloidal silicon dioxide
Abstract: A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.
Inventor(s): Haeberlin; Barbara (Munchenstein, CH), Kramer; Andrea (Reute, DE), Heuerding; Silvia (Basel, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:13/489,396
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use; Formulation; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis PharmAFINITOR DISPERZeverolimusTABLET, FOR SUSPENSION;ORAL203985-001Aug 29, 2012RXYesNo► Subscribe► SubscribeY► Subscribe
Novartis PharmAFINITOR DISPERZeverolimusTABLET, FOR SUSPENSION;ORAL203985-002Aug 29, 2012RXYesNo► Subscribe► SubscribeY► Subscribe
Novartis PharmAFINITOR DISPERZeverolimusTABLET, FOR SUSPENSION;ORAL203985-003Aug 29, 2012RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,617,598

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0123400.4Sep 28, 2001

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Accenture
Deloitte
Farmers Insurance
Johnson and Johnson
McKinsey
UBS
Queensland Health
Colorcon
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot